The U.S. Food and Drug Administration has approved Tryngolza (olezarsen) for adults with severe hypertriglyceridemia. The medicine is used with diet to lower triglycerides and reduce the risk of acute pancreatitis, a serious inflammation of the pancreas.
This update may be relevant to some people with diabetes because diabetes, obesity, alcohol use, kidney disease and some medicines can contribute to very high triglyceride levels. Tryngolza is not a diabetes medicine and does not replace treatment for blood glucose, blood pressure or cholesterol.
What is severe hypertriglyceridemia?
Triglycerides are a type of fat carried in the blood. The FDA defines severe hypertriglyceridemia as a fasting triglyceride level of at least 500 mg/dL. At this level, the risk of acute pancreatitis becomes an important concern.
Very high triglycerides can have more than one cause. Poorly controlled diabetes, excess weight, inherited lipid conditions, kidney disease, alcohol and some medicines may all play a role. A clinician will usually look for the underlying cause rather than treating the number alone.
What did the FDA approve?
Tryngolza is given as an injection under the skin once a month and is used alongside dietary treatment. The approval was supported by two randomized, placebo-controlled trials involving adults with severe hypertriglyceridemia.
Across the studies, Tryngolza lowered triglyceride levels more than placebo at six months. The size of the reduction varied by study and dose. The FDA also reported a lower rate of acute pancreatitis in the combined Tryngolza groups than in the placebo groups.
That result is important, but it does not mean pancreatitis risk disappears. People taking Tryngolza still need medical follow-up and should continue the diet and other care recommended by their clinician.
Why might this matter for people with diabetes?
High triglycerides can occur alongside type 2 diabetes, insulin resistance and obesity. When blood glucose is persistently high, the liver may produce more triglyceride-rich particles. Treating diabetes and other metabolic risk factors can therefore be part of managing triglycerides.
However, Tryngolza should not be described as a treatment for diabetes itself. It is approved for severe hypertriglyceridemia. It is not intended to lower HbA1c, replace insulin or replace other glucose-lowering medicines.
What side effects should patients know about?
The most common adverse reactions reported for the severe hypertriglyceridemia indication include reactions at the injection site and increases in liver enzymes. A clinician may check liver enzymes before treatment, after a dose increase or when clinically indicated.
Allergic reactions are possible. Seek urgent medical help for swelling of the face, trouble breathing, widespread hives, chills or other symptoms of a serious allergic reaction. Do not take another dose until a healthcare professional has advised you what to do.
Severe hypertriglyceridemia can also cause acute pancreatitis. Seek urgent medical care for persistent or severe upper-abdominal pain, especially if it spreads to the back, or if it occurs with repeated vomiting or fever.
Questions to ask your healthcare team
- Was my triglyceride test fasting, and what was the result?
- Could diabetes, alcohol, kidney disease, an inherited condition or another medicine be contributing?
- What dietary changes and other treatments do I need alongside Tryngolza?
- How will my liver enzymes and triglycerides be monitored?
- Which symptoms should prompt an urgent call or emergency assessment?
The bottom line
Tryngolza is a new monthly treatment for adults with severe hypertriglyceridemia. FDA-supported trial data show that it lowers triglycerides and reduces, but does not eliminate, the risk of acute pancreatitis. For people with diabetes, its relevance is indirect: it addresses a dangerous triglyceride problem, not blood glucose. Treatment decisions should be made with a healthcare professional who can consider the cause of the high triglycerides, other medicines, diet and overall cardiovascular risk.
This article is for general information and does not replace medical advice, diagnosis or treatment.